$QSI

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Other Events. Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protei

Original reporting
Published Oct 15, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$QSI
Bullish
high confidence
Mentioned
$QSI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QSIBullishLow
01

Why it matters

The compliance notice eliminates an immediate delisting threat, which can stabilize the stock and may attract short‑covering or new buying.

02

Market read

A micro‑cap stock regaining Nasdaq compliance is a modest but clear catalyst for short‑term price support.

03

What to watch

Potential upcoming financing needs or product milestones could drive future price moves.

Relevance 6/10Novelty 6/10Timing: today

Background

Quantum‑Si (Nasdaq: QSI) is a proteomics company focused on single‑molecule protein sequencing. The Nasdaq minimum bid price rule requires a $1.00 closing price for 10 consecutive days.

Company-level read

Ticker impact

$QSIBullishHigh confidence
Context

Quantum‑Si announced it has regained Nasdaq minimum bid price compliance, closing above $1 for 10 days.

Expected impact

potential modest upside as market prices in reduced listing risk

Evidence & confidence

The filing is the first public notice of compliance; investors typically react positively to removal of a delisting threat.

Market effects

Minimal impact on the broader proteomics/biotech sector.

Limited to U.S. Nasdaq-listed micro‑cap investors.

Low

Counterpoint

Some investors may view the compliance regain as a sign of prior weakness and remain cautious.

Key entities

  • Quantum‑Si Inc.

    Nasdaq‑listed proteomics firm

  • Nasdaq Listing Qualifications Department

    Entity that monitors listing compliance

Related articles

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$QSIMed

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

$QSIMedAI 8/10

Quantum-Si (QSI) Stock Falls on Q2 2026 Earnings

Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.

$QSIMed

Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new mark